Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Docetaxel
Drug: Carboplatin

First Posted Date: 2004-08-31

Last Posted Date: 2015-02-25

Lead Sponsor: Duke University

Target Recruit Count: 150

Registration Number: NCT00090610

Locations: 🇺🇸
Franklin Square Hospital Center/MedStar Health-Section of Hematology/Oncology, Baltimore, Maryland, United States
🇺🇸
Hope: A Woman's Cancer Center, Asheville, North Carolina, United States
🇺🇸
Columbia University College of Physicians and Surg, New York, New York, United States

and more 16 locations

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-31

Last Posted Date: 2010-10-01

Lead Sponsor: Temple University

Registration Number: NCT00002509

Locations: 🇺🇸
Temple University Cancer Center, Philadelphia, Pennsylvania, United States

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1

Conditions: Breast Cancer

First Posted Date: 2004-08-31

Last Posted Date: 2014-01-10

Lead Sponsor: St. Louis University

Target Recruit Count: 50

Registration Number: NCT00002628

Locations: 🇺🇸
Methodist Hospital-Central Unit, Memphis, Tennessee, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
St. Louis University Health Sciences Center, Saint Louis, Missouri, United States

Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors

Phase 2

Completed

Conditions: Extragonadal Germ Cell Tumor
Ovarian Cancer

First Posted Date: 2004-08-30

Last Posted Date: 2013-06-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002489

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Gemcitabine Plus Carboplatin or Cisplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-08-30

Last Posted Date: 2013-02-04

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Registration Number: NCT00004201

Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2004-08-26

Last Posted Date: 2013-07-09

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 45

Registration Number: NCT00003378

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States

and more 61 locations

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Precancerous/Nonmalignant Condition
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-08-26

Last Posted Date: 2013-03-26

Lead Sponsor: Cancer Treatment Centers of America

Target Recruit Count: 30

Registration Number: NCT00003406

Locations: 🇺🇸
Midwestern Regional Medical Center, Zion, Illinois, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions: Biological: filgrastim
Drug: amifostine trihydrate
Drug: carboplatin
Drug: cyclophosphamide
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-08-24

Last Posted Date: 2013-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 11

Registration Number: NCT00003136

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease

Phase 3

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-08-23

Last Posted Date: 2014-01-06

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00005024

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-23

Last Posted Date: 2013-05-30

Lead Sponsor: Hackensack Meridian Health

Registration Number: NCT00004906

Locations: 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy